Gilead Sciences Inc (NASDAQ:GILD) | Gilead Announces U.S. FDA Priority Review Designation for Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Chronic Hepatitis C Genotype 1 Infection

[Business Wire] – Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has granted priority review to the company’s New Drug Application for a once-daily fixed-dose combination of the NS5A . . . → Read More: Gilead Sciences Inc (NASDAQ:GILD) | Gilead Announces U.S. FDA Priority Review Designation for Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Chronic Hepatitis C Genotype 1 Infection Similar Articles: Company Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead Announces Settlement Method for 1.00% Convertible Senior Notes Due 2014 Gilead Sciences Inc. (NASDAQ:GILD) – Gilead to seek okay for combo hepatitis C pill in Q1 Stock Update: Johnson & Johnson (NYSE:JNJ) – J&J’s new hepatitis C drug gets positive FDA review